Transthyretin stabilizer therapy increases naturally-occurring antibodies in ATTR cardiomyopathy

Key Points

• This research aims to explore the relationship between transthyretin stabilizer therapy and naturally occurring antibodies in ATTR cardiomyopathy.
• Analysis of naturally-occurring TTR-targeting antibodies in individuals with ATTR cardiomyopathy.
• Examination of how therapy influences antibody levels and fibril formation.
• Increased levels of TTR-targeting antibodies were observed following transthyretin stabilizer therapy.
• The enhanced antibodies may inhibit fibril formation, impacting disease progression.